Seaport Therapeutics CEO Daphne Zohar (L) and chairman Steve Paul
Updated: Steve Paul, Daphne Zohar reunite for another neuro startup after Karuna success
That was quick.
One month after Bristol Myers Squibb completed its $14 billion acquisition of Karuna Therapeutics, the CNS biotech’s executive and founding …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
